巴曲酶治疗急性期脑梗死临床观察

目的探讨巴曲酶治疗急性期脑梗死的临床效果及其安全性。方法将急性期脑梗死患者,随机分为观察组37例和对照组37例,两组均采用0.9%氯化钠注射液加银杏达莫注射液20 mL静滴为基础,在此基础上,观察组第1 d静脉滴注巴曲酶10 BU,第3、5 d,各给予5.0 BU巴曲酶静脉滴注;对照组加用安慰剂静点。结果治疗后,观察组疗效神经功能缺损、评分明显低于对照组,差异有统计学意义(P<0.01)。观察患者的治愈率、显效率、总有效率,均明显高于对照组,差异有统计学意义(P<0.05)。结论巴曲酶治疗急性脑梗死的疗效显著,安全性好,无明显不良反应。

Batroxobin in the Treatment of Acute Cerebral Infarction

Objective To investigate the clinical effect and safety of batroxobin in the treatment of acute cerebral infarction.Methods The patients with acute cerebral infarction were randomly divided into observation group(37cases) and control group(37 cases).Both two groups were given 0.9% sodium chloride injection plus Yinxingdamo injection of 20 ml of a few drops.On the basis of original treatment the observation group was given intravenous infusion of batroxobin 10 BU on first day,and 5 BU batroxobin on third and fifth day;the control group was treated with placebo.Results After treatment,the neurological deficit score in observation group was significantly lower than the control group,the difference was statistically significant(P<0.01).The patients,the cure rate,efficiency,total effective rate was significantly higher,the difference was statistically significant(P<0.05).Conclusion Batroxobin treatment of acute cerebral infarction is security,and has no significant adverse reactions.